Prot #HCRN LUN18-335/NU MDA20L01: An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Project: Research project

Project Details

StatusActive
Effective start/end date1/14/21 → 1/14/27

Funding

  • Hoosier Cancer Research Network, Inc. ((OE) Prot #HCRN LUN18-335/NU MDA20L01 // (OE) Prot #HCRN LUN1...)
  • Lilly USA, LLC ((OE) Prot #HCRN LUN18-335/NU MDA20L01 // (OE) Prot #HCRN LUN1...)